SMART Brain Health in African-Americans
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 3/6/2019 |
| Start Date: | June 16, 2018 |
| End Date: | August 30, 2019 |
| Contact: | Marjorie C. Gondré-Lewis, Ph.D. |
| Email: | mgondre-lewis@Howard.edu |
| Phone: | 202-806-5274 |
A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use Disorder
The investigators hypothesize that opioid use in African-Americans will be associated with
hypodopaminergic alleles that alter the threshold for activating feelings of reward and
pleasure within the dopaminergic system, and that these allelic frequencies will differ
significantly from European Americans. Planned is a targeted system to study genetic risks
for reward deficiency using risk gene panel to assign a genetic addiction risk score (GARS),
comprehensive surveys to determine quality of life and exposure to stressors and trauma. This
system will allow prediction of addiction and relapse potential and delivery of personalized
treatment.
hypodopaminergic alleles that alter the threshold for activating feelings of reward and
pleasure within the dopaminergic system, and that these allelic frequencies will differ
significantly from European Americans. Planned is a targeted system to study genetic risks
for reward deficiency using risk gene panel to assign a genetic addiction risk score (GARS),
comprehensive surveys to determine quality of life and exposure to stressors and trauma. This
system will allow prediction of addiction and relapse potential and delivery of personalized
treatment.
Individuals seeking treatment for Opioid Use Disorder in the Washington DC metro area will be
recruited to this Study, which consists of 1) early pre-disposition diagnosis using the
Genetic Addiction Risk Score (GARS); 2) Assessment of reward deficiency, co-morbid
neuropsychiatric disease, quality of life/happiness, stressors/trauma and other psychometric
measurements using validated questionnaires; Urine drug testing during actual treatment that
uses comprehensive analysis of reported drugs to determine compliance with prescription
medications and non-abstinence to illicit drugs; and 4) adjunctive treatment with
neuroadaptogen amino acid therapy (NAAT), a glutaminergic-dopaminergic optimization
nutraceutical (generic name: KB220) compared to placebo, aimed to prevent relapse by
induction of dopamine homeostasis.
recruited to this Study, which consists of 1) early pre-disposition diagnosis using the
Genetic Addiction Risk Score (GARS); 2) Assessment of reward deficiency, co-morbid
neuropsychiatric disease, quality of life/happiness, stressors/trauma and other psychometric
measurements using validated questionnaires; Urine drug testing during actual treatment that
uses comprehensive analysis of reported drugs to determine compliance with prescription
medications and non-abstinence to illicit drugs; and 4) adjunctive treatment with
neuroadaptogen amino acid therapy (NAAT), a glutaminergic-dopaminergic optimization
nutraceutical (generic name: KB220) compared to placebo, aimed to prevent relapse by
induction of dopamine homeostasis.
Inclusion Criteria:
- Must be able to consent and understand questions being asked during surveys
- Must be willing to undergo pharmacogenetic testing
- Must be able to swallow tablets
Exclusion Criteria:
- Clinical Diagnosis of Alzheimer's disease/Dementia
- Clinical Diagnosis of Schizophrenia
- Clinical Diagnosis of a terminal disorder
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials